Interim CEO Invests $50K in Open Market Purchase at Significant Premium
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion Pharmaceuticals' Interim CEO, Gary S. Stetz, purchased $50,000 worth of common stock at $0.04 per share, a substantial premium to the current market price of $0.0013, representing over 10% of the company's market cap.
Key Events · Ownership and Investor Activity · CTRVP
-
Interim CEO Makes Significant Purchase
Gary S. Stetz, Interim CEO and Director, acquired 1,250,000 shares of common stock for $50,000 in an open market transaction on April 21, 2026.
-
Purchase at Substantial Premium
The transaction was executed at $0.04 per share, which is significantly above the current market price of $0.0013.
-
Substantial Investment Relative to Market Cap
The $50,000 purchase represents approximately 10.5% of the company's current market capitalization.
-
Transaction Linked to Recent Private Placement
This purchase likely forms part of the $700,000 private placement at $0.04 per share, which was previously disclosed on April 22, 2026.
Analysis · CTRVP · Life Sciences
This significant open market purchase by Interim CEO Gary S. Stetz demonstrates extremely strong conviction in Hepion Pharmaceuticals. On April 21, 2026, Mr. Stetz invested $50,000 to acquire 1,250,000 shares at $0.04 per share. This transaction, which appears to be part of the $700,000 private placement disclosed on April 22, 2026, represents over 10% of the company's market capitalization. The fact that the CEO purchased shares at $0.04, a price substantially higher than the current market price of $0.0013 (which is also near its 52-week high), indicates a strong belief in the company's long-term value despite recent market performance.
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $476.4K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.